4//SEC Filing
Ragosa Mark 4
Accession 0001835458-25-000005
CIK 0001730430other
Filed
Nov 13, 7:00 PM ET
Accepted
Nov 14, 4:35 PM ET
Size
9.1 KB
Accession
0001835458-25-000005
Insider Transaction Report
Form 4
Ragosa Mark
CHIEF FINANCIAL OFFICER
Transactions
- Exercise/Conversion
Class A Ordinary Share
2025-11-12$30.93/sh+19,900$615,507→ 50,986 total - Sale
Class A Ordinary Share
2025-11-12$40.94/sh−19,900$814,706→ 31,086 total - Exercise/Conversion
Share Option
2025-11-12−19,900→ 0 totalExercise: $30.93Exp: 2028-09-19→ Class A Ordinary Share (19,900 underlying)
Footnotes (3)
- [F1]This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024.
- [F2]This transaction was executed in multiple trades through a broker-dealer at prices ranging between $40.93 and $41.035. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
- [F3]The option is fully vested and exercisable.
Documents
Issuer
Kiniksa Pharmaceuticals International, plc
CIK 0001730430
Entity typeother
Related Parties
1- filerCIK 0001835458
Filing Metadata
- Form type
- 4
- Filed
- Nov 13, 7:00 PM ET
- Accepted
- Nov 14, 4:35 PM ET
- Size
- 9.1 KB